Purpose: The US Food and Drug Administration (FDA) approved elacestrant for the treatment of postmenopausal women or adult men with estrogen receptor-positive
We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or
BRCAwt, BRCA wildtype; gBRCA, carrier of a pathogenic or likely
Safety and antitumor activity of pembrolizumab in patients with estrogen Receptor–Positive/Human epidermal growth factor receptor 2–Negative advanced
Breast cancer
Survival rates for women with metastatic breast cancer (m bc a) are improving, especially for those whose tumours express the estrogen or progesterone
Of these, about 70% are hormone receptor-positive and HER2-negative, meaning the tumor cells contain receptors for estrogen or progesterone but low levels of
In contrast, the addition of capecitabine in the adjuvant setting led to improved outcomes for OS and DFS in hormone receptor-negative cancer
There is an undisputable need for new treatment options in endocrine-resistant hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+ and HER2–) metastatic breast cancer that is resistant to conventional therapies
This article provides an overview of the current evidence and guidelines for this subtype of breast cancer, as well as the challenges and opportunities for future research
In 2017, Nerlynx (neratinib) was also approved for people with early-stage HER2-positive breast cancers following treatment with Herceptin
Women diagnosed with early-stage, HER2-negative breast cancer with residual disease who were treated with Xeloda after surgery had better survival compared to women who didn't get chemotherapy after surgery
Both histologic assessments including a status of estrogen receptor (ER), progesterone receptor (PR), HER2/neu (HER2), and Ki-67 and cancer staging are crucial to helping guide treatment recommendations
The second indication is in combination with capecitabine (Xeloda) for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received 2 or more prior Breast cancers that test negative for both hormone receptors are HR-negative
HER2-low: HER2-low is a new designation that may be found in breast cancers that are either HR-positive or HR-negative
There was no benefit with the addition of chemotherapy to endocrine therapy in
CDK4/6 inhibitors have transformed the approach to therapy along with the identification
Oophorectomy was first shown to cause regression of unresectable breast cancer in 1896, and since then, estrogen receptor modulation and estrogen deprivation have become standards of care for hr